Eu Biologics (KRX: 206650)
Who is buying Eu Biologics?
Between Sep 15, 2026 and Oct 16, 2026 (20 trading sessions), foreign investors net sold ₩0.4bn ($0M) of Eu Biologics, the 342nd largest foreign net sale among 1828 KOSDAQ stocks. Institutions were flat and retail investors net bought ₩0.3bn ($0M) over the same window. Foreigners were net buyers on 9 of the 20 sessions.
Foreign investors hold 5.88% of Eu Biologics' listed shares (KRX ownership data as of Oct 16, 2026), down from 6.21% twenty sessions earlier and 7.9% a year ago.
The stock closed at ₩8,080 on Oct 16, 2026: -6.48% over 20 sessions, -28.87% year-to-date, -36.53% over one year. The 52-week range is ₩6,950 – ₩17,700.
At ₩8,080 the stock trades at 7.17× trailing earnings (KRX, last completed fiscal year); no analyst consensus is available for a forward P/E.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-16 | ₩8,080 | +₩0.4bn | ₩0.0bn | ₩-0.4bn |
| 2026-10-15 | ₩7,780 | +₩0.2bn | ₩0.0bn | ₩-0.2bn |
| 2026-10-14 | ₩8,100 | +₩0.1bn | ₩0.0bn | ₩-0.1bn |
| 2026-10-13 | ₩8,140 | +₩0.2bn | ₩0.0bn | ₩-0.2bn |
| 2026-10-12 | ₩8,100 | ₩-0.3bn | ₩0.0bn | +₩0.3bn |
| 2026-10-08 | ₩8,420 | ₩-1.0bn | ₩0.0bn | +₩1.0bn |
| 2026-10-07 | ₩8,490 | ₩-0.0bn | ₩0.0bn | +₩0.0bn |
| 2026-10-06 | ₩8,430 | ₩-0.0bn | ₩0.0bn | +₩0.0bn |
| 2026-10-02 | ₩8,450 | ₩-0.2bn | ₩0.0bn | +₩0.1bn |
| 2026-10-01 | ₩8,630 | +₩0.3bn | ₩0.0bn | ₩-0.3bn |
| 2026-09-30 | ₩8,290 | +₩0.0bn | ₩0.0bn | ₩-0.0bn |
| 2026-09-29 | ₩8,230 | ₩-0.2bn | ₩0.0bn | +₩0.2bn |
| 2026-09-28 | ₩8,420 | +₩0.2bn | ₩0.0bn | ₩-0.2bn |
| 2026-09-23 | ₩8,240 | ₩-0.1bn | ₩0.0bn | +₩0.1bn |
| 2026-09-22 | ₩8,320 | ₩-0.0bn | ₩0.0bn | +₩0.0bn |
| 2026-09-21 | ₩8,370 | ₩-0.1bn | ₩0.0bn | +₩0.0bn |
| 2026-09-18 | ₩8,410 | ₩-0.1bn | ₩0.0bn | +₩0.1bn |
| 2026-09-17 | ₩8,320 | +₩0.1bn | ₩0.0bn | ₩-0.1bn |
| 2026-09-16 | ₩8,320 | ₩-0.0bn | ₩0.0bn | +₩0.0bn |
| 2026-09-15 | ₩8,400 | +₩0.1bn | ₩0.0bn | ₩-0.1bn |
| 2026-09-14 | ₩8,640 | ₩-0.1bn | ₩0.0bn | +₩0.1bn |
| 2026-09-11 | ₩8,690 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-09-10 | ₩8,550 | +₩0.2bn | ₩-0.4bn | +₩0.3bn |
| 2026-09-09 | ₩8,650 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-09-08 | ₩8,500 | ₩-0.3bn | ₩0.0bn | +₩0.3bn |
| 2026-09-07 | ₩8,620 | ₩-0.3bn | +₩0.0bn | +₩0.3bn |
| 2026-09-04 | ₩8,790 | ₩-0.0bn | +₩0.1bn | ₩-0.0bn |
| 2026-09-03 | ₩8,690 | ₩-0.2bn | +₩0.0bn | +₩0.2bn |
| 2026-09-02 | ₩8,940 | ₩-0.5bn | +₩0.1bn | +₩0.5bn |
| 2026-09-01 | ₩9,290 | +₩0.1bn | +₩0.1bn | ₩-0.2bn |
| 2026-08-31 | ₩9,110 | ₩-0.9bn | +₩0.1bn | +₩0.9bn |
| 2026-08-28 | ₩9,510 | +₩0.7bn | +₩0.1bn | ₩-0.8bn |
| 2026-08-27 | ₩8,830 | ₩-0.3bn | +₩0.0bn | +₩0.3bn |
| 2026-08-26 | ₩9,000 | +₩0.1bn | ₩0.0bn | +₩0.3bn |
| 2026-08-25 | ₩8,950 | +₩0.1bn | +₩0.0bn | ₩-0.2bn |
| 2026-08-24 | ₩9,020 | +₩0.1bn | ₩0.0bn | ₩-0.1bn |
| 2026-08-21 | ₩8,660 | ₩-0.3bn | ₩-0.0bn | +₩0.3bn |
| 2026-08-20 | ₩8,660 | ₩-0.1bn | +₩0.0bn | +₩0.0bn |
| 2026-08-19 | ₩8,580 | ₩-0.4bn | ₩0.0bn | +₩0.4bn |
| 2026-08-18 | ₩9,150 | ₩-0.3bn | ₩-0.0bn | +₩0.2bn |
| 2026-08-14 | ₩9,130 | +₩0.1bn | ₩0.0bn | ₩-0.1bn |
| 2026-08-13 | ₩8,870 | ₩-0.3bn | +₩0.0bn | +₩0.3bn |
| 2026-08-12 | ₩8,960 | ₩-0.2bn | ₩0.0bn | +₩0.2bn |
| 2026-08-11 | ₩9,120 | +₩0.0bn | ₩-0.0bn | ₩-0.1bn |
| 2026-08-10 | ₩9,150 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-07 | ₩8,690 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-08-06 | ₩8,730 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-05 | ₩8,400 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-08-04 | ₩8,340 | +₩0.1bn | ₩0.0bn | ₩-0.1bn |
| 2026-08-03 | ₩7,870 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-07-31 | ₩7,930 | +₩0.1bn | ₩0.0bn | ₩-0.1bn |
| 2026-07-30 | ₩7,440 | +₩0.5bn | +₩0.0bn | ₩-0.5bn |
| 2026-07-29 | ₩7,390 | +₩0.0bn | +₩0.0bn | ₩-0.1bn |
| 2026-07-28 | ₩7,850 | +₩0.0bn | ₩0.0bn | ₩-0.0bn |
| 2026-07-27 | ₩8,070 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-07-24 | ₩7,720 | ₩-0.2bn | +₩0.0bn | +₩0.2bn |
| 2026-07-23 | ₩7,890 | +₩0.3bn | ₩0.0bn | ₩-0.3bn |
| 2026-07-22 | ₩7,620 | ₩-0.3bn | ₩0.0bn | +₩0.1bn |
| 2026-07-21 | ₩7,620 | +₩0.4bn | ₩0.0bn | ₩-0.4bn |
| 2026-07-20 | ₩7,600 | +₩0.2bn | ₩-0.3bn | +₩0.1bn |
| 2026-07-16 | ₩7,980 | +₩0.1bn | ₩-0.1bn | ₩-0.0bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩0.4bn | +$0M | ₩0.0bn | ₩-0.4bn |
| 5 days | +₩0.7bn | +$1M | ₩0.0bn | ₩-0.7bn |
| 20 days | ₩-0.4bn | $-0M | ₩0.0bn | +₩0.3bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Eu Biologics stock?
Over the last 5 sessions foreign investors net bought ₩0.7bn ($1M) of Eu Biologics; over 60 sessions they net sold ₩2.1bn ($2M); since Jan 1, 2026 they net sold ₩5.4bn ($4M). Over 20 sessions the stock is the 342nd largest foreign net sale among 1828 KOSDAQ stocks.
How much of Eu Biologics do foreign investors own?
Foreign investors own 5.88% of Eu Biologics' shares as of Oct 16, 2026, versus 7.9% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions were flat and retail investors net bought ₩0.3bn ($0M) of Eu Biologics. Foreign selling is being absorbed mainly by retail buying.
Is Eu Biologics listed on KOSPI or KOSDAQ?
Eu Biologics (유바이오로직스) trades on KOSDAQ under KRX code 206650 in the Biotech & Pharma group, with a market capitalization of ₩0T ($0.2B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩69bn ($52M) | – | ₩8bn ($6M) | -₩15bn (-$11M) |
| 2024 | ₩96bn ($71M) | +38.40% | ₩34bn ($26M) | ₩19bn ($14M) |
| 2025 | ₩149bn ($111M) | +55.40% | ₩61bn ($45M) | ₩41bn ($31M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1345.9/$) for reference only.